SCHEMBL19706137

SCHEMBL19706137

Nc1ccc(-c2cccc(C(F)(F)F)c2)nc1N(C(=O)Nc1ccc(N2CCCCC2)cc1)C1CCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCHR1 Q99705 1/20 0.43
▸ RAB9A P51151 2/20 0.42
▸ POLB P06746 2/20 0.42
▸ CA2 P00918 2/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ FPR1 P21462 1/20 0.41
▸ FPR2 P25090 1/20 0.41
▸ ATR Q13535 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ KIF11 P52732 1/20 0.38
▸ UBE2M P61081 1/20 0.38
▸ DCUN1D1 Q96GG9 1/20 0.38
▸ TRPV1 Q8NER1 3/20 0.37
▸ CNR1 P21554 3/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ PAX8 Q06710 1/20 0.37
▸ RAF1 P04049 1/20 0.37
▸ BRAF P15056 1/20 0.37
▸ CA12 O43570 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19365571 0.99 MCHR1 (0.42) MCHR1RAB9APOLBCA2CA9
SCHEMBL19365306 0.88 POLB (0.44) MCHR1RAB9APOLBCA2CA9
SCHEMBL19365636 0.88 POLB (0.46) MCHR1RAB9APOLBCA2CA9
SCHEMBL19365722 0.86 POLB (0.41) MCHR1RAB9APOLBCA2CA9
SCHEMBL19365519 0.84 POLB (0.46) MCHR1RAB9APOLBKIF11UBE2M
SCHEMBL19670603 0.83 POLB (0.43) MCHR1RAB9APOLBCA2CA9
SCHEMBL19365784 0.83 POLB (0.47) MCHR1RAB9APOLBUBE2MDCUN1D1
SCHEMBL19670601 0.82 POLB (0.41) MCHR1RAB9APOLBCA2CA9
SCHEMBL19670560 0.82 POLB (0.47) MCHR1RAB9APOLBCA2CA9
SCHEMBL21841343 0.81 KMO (0.41) MCHR1RAB9APOLBCA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2020-03-17 — — US disclosed
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2017-12-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 MCHR1 4256/4885RAB9A 1471/4885POLB 961/4885
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators SIRT1, SIRT3, SIRT2 MCHR1 4256/4885RAB9A 1471/4885POLB 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback